Allergic Study of Ivermectin Microemulsion

The study was aimed to observe the allergic reaction of ivermectin microemulsion injection on animals. Active systemic allergy test and passive cutaneous anaphylaxis test were carried out to study the allergic reaction of ivermectin microemulsion injection on Wistar rat and guinea pig, respectively, according to . The results showed that the allergic reaction of ivermectin microemulsion injection on Wistar rat and guinea pig were both negative. The study provided experiment evidences for the safety evaluation of ivermectin microemulsion.     

北京市空气污染物对过敏性鼻炎的影响研究

 以2009年3月19日至2010年3月18日间北京医院耳鼻喉—头颈外科的过敏性鼻炎（AR）门诊就诊病人观测为基础，结合北京市空气质量，探讨空气质量与AR的关系。结果表明， AR患者的人数均随年龄的增长呈现先增加后减少的趋势，以中青年龄段（21～50岁）人数最多。春、秋季是过敏性鼻炎的易发时期，夏、冬季发病率相对较低。AR日就诊人数的时间变化趋势与空气中PM10，SO2，NO2的浓度变化具有一定的时间对应性，在观测的上半期内尤为明显，表明在短期内空气中PM10，SO2，NO2浓度的增加会直接影响AR的发生与症状加重，并导致就诊人数增加     

红车轴草总黄酮对小鼠免疫功能的影响

［目的］研究红车轴草总黄酮对小鼠免疫功能的影响。［方法］设计迟发变态反应试验、炭粒廓清试验、脏器指数试验，每个试验均用40只小鼠，随机分成4组，设对照组与高、中、低剂量3个试验组。3个试验组分别给予85 mg/（kg·d）（高剂量组），53 mg/（kg·d）（中剂量组），22 mg/（kg·d）（低剂量组）红车轴草总黄酮灌胃，对照组以吐温-盐水液灌胃。［结果］3个试验组48 h足跖增厚与对照组均有增加，以中剂量试验组增加显著（P〈0.05）；中剂量组与低剂量组的吞噬指数较对照组有显著增高（P〈0.05）；脏器指数试验结果表明，试验组与对照组均有增加，但没有显著的统计学意义。［结论］试验全面评价了红车轴草总黄酮的各种生理药理功能及其对免疫功能的影响，为其开发应用提供了可靠的参考资料。     

牛源非典型分枝杆菌的分离与鉴定

对我国东北和华北地区牛群中非典型分枝杆菌的感染情况进行了调查，从５２头结核（副结核）菌素变态反应阳性及可疑牛的１４２份巴结等材料和在屠宰场预备屠宰的２００头猪（肉）牛（其中８头结核菌素变态反应阳性或可疑）的５６９份淋巴结材料中分离出２０株分枝杆菌。经鉴定牛分枝杆菌３株，非典型分枝杆菌１７株。非典型分枝杆菌进一步被鉴定为：瘰疠分枝杆菌５株，偶发分枝杆菌４株，鸟－胞内分枝杆菌复合物４株，副结核分枝杆菌     

牛源分枝杆菌变应原对免疫豚鼠变态反应试验

本文采用牛结核PPD检出阳性牛分离的分枝杆菌(包括有牛分枝杆菌、瘰疬分枝杆菌、乌胞内分枝杆菌2型及9型、副结核分枝杆菌、偶发分枝杆菌以及草分枝杆菌等),制成灭活免疫原进行豚鼠接种,并以各种分枝杆菌PPD进行变态反应检查,以观察其发生交叉反应的情况。试验结果表明:各种分枝杆菌除发生主反应外,均表现出明显的相互交叉的变态反应,尤以瘰疬分枝杆菌、乌胞内分杆菌2型及9型、副结核分枝杆菌以及牛分枝杆菌等交叉严重。提示:在牛结核及副结核的检疫中出现其它分枝杆菌干扰的假阳性反应。     

牛副结核检疫中的非特异性干扰

给犊牛接种各种分枝杆菌，然后以副结核ＰＰＤ进行变态反应试验，观察各分枝杆菌感染对副结核变态反应的干扰；从各种分枝杆菌感染牛群采取血清进行副结核ＥＬＩＳＡ检测，以观察各分枝杆菌血清对牛副结核ＥＬＩＳＡ的干扰。结果：多种分枝杆菌，特别是鸟胞内分枝杆菌、瘰疬分枝杆菌的感染可干扰副结核变态反应；部分结核牛血清干扰副结核ＥＬＩＳＡ的检测     

Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs

BACKGROUND: Glucocorticoids with or without other immunotherapy are the initial treatment of choice for dogs with severe immune-mediated thrombocytopenia (IMT). The majority of treated dogs will have improvements in platelet counts within 5 to 7 days of starting therapy, but complications from hemorrhage often occur before a response is seen. Human IV immunoglobulin (hIVIG) blocks Fc receptors on mononuclear phagocytic cells in dogs; it is used in people with idiopathic thrombocytopenic purpura. HYPOTHESIS: The purpose of this study was to describe adverse effects and benefit of hIVIG in addition to conventional immunosuppressive therapy in dogs with severe IMT. ANIMALS: Five client-owned dogs with severe primary IMT. METHODS: Case series. The hospital database was searched for dogs with primary IMT treated with hIVIG. RESULTS: No adverse effects were noted during or after hIVIG infusion in any treated dog. Over a 6-month follow-up, all dogs were clinically normal when using conventional immunosuppressive therapy. Human IVIG was administered 3 days after initiation of immunosuppressive therapy in 4 dogs, and, after 2 days, in 1 dog. In all dogs, the mean platelet counts pre- and 24 hours post-hIVIG infusion (0.28-0.76 g/kg) were 2,500/pL and 50,600/microL (62,750/microL for the 4 responders), respectively. One dog failed to respond as promptly to hIVIG (0.34 g/kg), and the platelet count increased to 66,000/microL after 9 days of immunosuppressive therapy. The mean duration of hospitalization post-hIVIG in all 5 dogs was 1.8 days (12 hours for responders), and the mean total length of hospitalization was 4.6 days (3.5 days for responders). Active hemorrhage resolved and no packed red blood cell transfusions were required after hIVIG infusion for responders. CONCLUSIONS AND CLINICAL IMPORTANCE: Human IVIG was well tolerated and appeared to be associated with rapid platelet count recovery and amelioration of clinical signs in most dogs with IMT.